Couverture de Wegovy Faces Global Competition as South Korea Seeks Insurance Coverage and Novo Nordisk Develops Oral Alternative

Wegovy Faces Global Competition as South Korea Seeks Insurance Coverage and Novo Nordisk Develops Oral Alternative

Wegovy Faces Global Competition as South Korea Seeks Insurance Coverage and Novo Nordisk Develops Oral Alternative

Écouter gratuitement

Voir les détails

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
# Wegovy's Global Battle: Insurance Fights, Oral Pills & Rising Competition from Eli Lilly **Episode Description:** The Wegovy story has evolved far beyond a weekly injection and weight loss numbers — it's now a global battle over healthcare access, pricing, and the future of obesity treatment. In this episode, we break down the latest developments shaking up the obesity drug market worldwide. **What we cover:** 🇰🇷 **South Korea's Insurance Showdown** – Novo Nordisk has formally applied for national health insurance reimbursement for Wegovy through South Korea's HIRA agency, seeking coverage for adolescent obesity, severe obesity, and cardiovascular risk reduction. We explain what this means for patient affordability and the regulatory hurdles ahead. 💊 **Domestic Competition Heats Up** – Hanmi Pharmaceutical's new obesity drug "Efpe" is set to launch in South Korea, offering a homegrown alternative to Wegovy — even if clinical results show slightly lower weight loss outcomes. 📈 **The Oral Wegovy Opportunity** – Citi analysts project the Wegovy tablet could generate $13 billion in annual sales. We discuss why a pill form could be a game-changer for needle-averse patients and what it means for Novo Nordisk's market position. ⚔️ **Eli Lilly's Growing Threat** – Mounjaro and Zepbound are gaining ground, with some reports showing Lilly's drugs overtaking Ozempic and Wegovy in key prescription metrics. Plus, we unpack Novo Nordisk's disappointing CagriSema trial results. 🩺 **New Liver Health Findings** – Fresh data presented at the European Association for the Study of Diabetes meeting reveals promising reductions in liver fat among semaglut Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment